Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease
NCT: NCT07060547 · RECRUITING
Brief Summary
This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data to better monitor and treat patients who have been affected by alcohol-associated liver disease. The study has 4 visits at an outpatient clinic at 1, 3, 6, and 12 months. At each of these visits, participants will undergo a HepQuant DuO test and other standard tests. In addition, the study team will ask about a participant's alcohol use, symptoms, and quality of life.
Frequently Asked Questions
What is Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease?
Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease is a clinical trial registered under NCT07060547. Current status: RECRUITING.
What is the status of NCT07060547?
The current status of NCT07060547 (Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease) is: RECRUITING.
When did Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease start?
Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease started on 2025-06-10.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.